PLx Pharma PLXP

$ 0.09 -27.8%

Quarterly report 2022-Q3
added 11-10-2022

PLx Pharma Balance Sheet 2011-2024 | PLXP

Annual Balance Sheet PLx Pharma

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-21.8 M	-9.72 M	-7.06 M	-17.5 M	-14.9 M	-5.23 M	-27 M	-3.86 M	-1.46 M	-
Long Term Debt	-	-	622 K	4.28 M	6.94 M	-	-	-	-	-	-
Long Term Debt Current	-	622 K	3.66 M	2.91 M	-	-	-	-	-	-	-
Total Non Current Liabilities	-	34 M	24.5 M	7.21 M	22.4 M	-	-	-	-	-	-
Total Current Liabilities	11.9 M	3.54 M	6.09 M	4.73 M	1.82 M	-	-	-	-	-	-
Total Liabilities	25 M	37.5 M	30.6 M	11.9 M	24.2 M	2.12 M	1.61 M	1.26 M	824 K	162 K	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-148 M	-102 M	-86.9 M	-66.4 M	-67.3 M	-62.4 M	-41.1 M	-22.3 M	-	-	-
Total Assets	76.6 M	26.6 M	18.5 M	18.4 M	28.8 M	17.1 M	32.4 M	27.2 M	4.03 M	1.47 M	-
Cash and Cash Equivalents	69.4 M	22.4 M	14 M	14.3 M	24.4 M	59.3 K	5.23 M	27 M	3.86 M	-	-
Book Value	51.7 M	-10.9 M	-12.1 M	6.44 M	4.62 M	15 M	30.8 M	25.9 M	3.21 M	1.31 M	-
Total Shareholders Equity	35.7 M	-10.9 M	-12.1 M	6.44 M	4.62 M	-2.32 M	30.8 M	25.9 M	-	-	-

All numbers in USD currency

Quarterly Balance Sheet PLx Pharma

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	622 K	622 K	622 K	622 K	4.28 M	4.28 M	4.28 M	4.28 M	6.94 M	6.94 M	6.94 M	6.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	7.02 M	12 M	18.9 M	25 M	44.9 M	29.2 M	22.3 M	16.2 M	16.2 M	16.2 M	16.2 M	16.9 M	16.9 M	16.9 M	16.9 M	11.9 M	11.9 M	11.9 M	11.9 M	24.2 M	24.2 M	24.2 M	24.2 M	2.94 M	2.94 M	2.94 M	2.12 M	1.61 M	1.61 M	1.61 M	1.61 M	1.26 M	1.26 M	1.26 M	1.26 M	824 K	824 K	824 K	824 K	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-179 M	-171 M	-159 M	-148 M	-152 M	-130 M	-114 M	-102 M	-102 M	-102 M	-102 M	-86.9 M	-86.9 M	-86.9 M	-86.9 M	-66.4 M	-66.4 M	-66.4 M	-66.4 M	-67.3 M	-67.3 M	-67.3 M	-67.3 M	-52 M	-52 M	-52 M	-62.4 M	-41.1 M	-41.1 M	-41.1 M	-41.1 M	-22.3 M	-22.3 M	-22.3 M	-22.3 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	33.2 M	44.5 M	60.9 M	76.6 M	91.8 M	85.3 M	88.3 M	26.6 M	26.6 M	26.6 M	26.6 M	18.5 M	18.5 M	18.5 M	18.5 M	18.4 M	18.4 M	18.4 M	18.4 M	28.8 M	28.8 M	28.8 M	28.8 M	616 K	616 K	616 K	17.1 M	32.4 M	32.4 M	32.4 M	32.4 M	27.2 M	27.2 M	27.2 M	27.2 M	4.03 M	4.03 M	4.03 M	4.03 M	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	25.8 M	35.7 M	52.5 M	69.4 M	82.6 M	80.2 M	84.4 M	22.4 M	22.4 M	22.4 M	22.4 M	14 M	14 M	14 M	14 M	14.3 M	14.3 M	14.3 M	14.3 M	24.4 M	24.4 M	24.4 M	24.4 M	59.3 K	59.3 K	59.3 K	16.7 M	91.7 K	5.23 M	5.23 M	5.23 M	27 M	27 M	27 M	27 M	3.86 M	3.86 M	3.86 M	3.86 M	1.46 M	-	-	-	-	-	-	-
Book Value	-	26.2 M	32.5 M	42 M	51.7 M	46.9 M	56.1 M	66 M	10.5 M	10.5 M	10.5 M	10.5 M	1.57 M	1.57 M	1.57 M	1.57 M	6.44 M	6.44 M	6.44 M	6.44 M	4.62 M	4.62 M	4.62 M	4.62 M	-2.32 M	-2.32 M	-2.32 M	15 M	30.8 M	30.8 M	30.8 M	30.8 M	25.9 M	25.9 M	25.9 M	25.9 M	3.21 M	3.21 M	3.21 M	3.21 M	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	10.2 M	16.5 M	26 M	35.7 M	30.9 M	40.1 M	44.7 M	-10.9 M	-10.9 M	-10.9 M	-10.9 M	-12.1 M	-12.1 M	-12.1 M	-12.1 M	6.44 M	6.44 M	6.44 M	6.44 M	4.62 M	4.62 M	4.62 M	4.62 M	-2.32 M	-2.32 M	-2.32 M	15 M	114 K	30.8 M	30.8 M	30.8 M	25.9 M	25.9 M	25.9 M	-	3.21 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency